Recurrent Primary Peritoneal Cancer
2 clinical trials · Condition
◉ Watch Recurrent Primary Peritoneal Cancer
| Record | Firm | Date |
|---|---|---|
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340) | Regeneron Pharmaceuticals | 2018-05-21 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01853644) | Northwestern University | 2013-06-06 |
Track Recurrent Primary Peritoneal Cancer automatically
Every clearance here is in the API, with alerts when new ones post.